M.A. Medical Sciences (University of Cambridge)
B.M. B.S. (University of Oxford)
Member of Royal College of Physicians UK
Fellow of Royal College of Pathologists
MBChB Year 5, MBChB Year 4, MBChB Year 3, MBChB Year 2, MBChB Year 1, BMedSci 3, BMedSci 2, BMedSci 1, Clinical Oncology MSc/PG Dip
Professor Moss makes substantial contributions to teaching at many levels, both within the University of Birmingham and beyond. He is currently Programme Director of the Intercalated Batchelor in Medical Sciences (Clinical Sciences) which offers medical students the opportunity to undertake an 8 month research project during their undergraduate degree. The course also has a dedicated programme of lecturers within the 6 themes of haematology, infection, histopathology, cancer studies, immunology and metabolic medicine.
Cancer Cell Biology, Clinical Trials, Tumour Immunology and Immune/Gene Therapy, Viral Oncology
Professor Moss’s research is focussed around the application of translational immunological research in the study of human disease. His current research group includes clinical and non-clinical research scientists working on a range of different projects:
The role of cytomegalovirus infection in human health and disease
Mechanisms of graft-versus-leukaemia following stem cell transplantation
The immune response against cancers
The Immunology of pregnancy
The role of DARC mutation in the development of ethnic neutropenia
Clinical Activity/NHS Affiliation
Professor Moss is an honorary consultant at the University Hospitals Birmingham NHS Foundation Trust. His primary interests are in haemato-oncology and general haematology and he is the Clinical Service Lead for chronic lymphocytic leukaemia.
Professor Moss is currently Chair of the Infections and Immunity Board at the Medical Research Council. In this role he oversees funding in basic, clinical and translational research applied to infectious human disease and to disorders of the human immune system. He also serves as a member of the Strategy Board at the MRC.
In addition he has previously held a number of important academic appointments:
- Chair of the Cancer Research UK (CRUK) Clinical and Translational Research Committee (2008-2012)
- Member of the Wellcome Trust Clinical Interview Committee
- Deputy Chair of the MRC Infections and Immunity Board 2009-2013
- Output assessor for Clinical Medicine Panel of Research Excellence Framework 2014 (REF2014)
Professor Moss is also a member of the Scientific Advisory Board of Cell Medica.
MD Morgan, CJ Day, KP Piper, N Khan, L Harper, P Moss, COS Savage (2010) Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells.
G Chakupurakal, D Onion, M Cobbold, V Mautner, P Moss (2009) Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7
S Nicholls, KP Piper, F Mohammed, TR Dafforn, S Tenzer, M Salim, P Mahendra, CF Craddock, P van Endert, H Schild, M Cobbold, VH Engelhard, P Moss, BE Willcox (2009) Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition
Proceedings of the National Academy of Sciences of the United States of America 106 3889-94
S Chidrawar, N Khan, W Wei, A McLarnon, N Smith, L Nayak, P Moss (2009) Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals.
Clinical and experimental immunology 155 423-32
HM McGettrick, K Hunter, P Moss, CD Buckley, GE Rainger, GB Nash (2009) Direct observations of the kinetics of migrating T cells suggest active retention by endothelial cells with continual bidirectional migration
Journal of Leukocyte Biology 85 98-107